等待開盤 05-22 09:30:00 美东时间
-0.150
-4.10%
今日重点评级关注:Needham:维持Artiva Biotherapeutics"买入"评级,目标价从18美元升至41美元;HC Wainwright & Co.:维持SAB Biotherapeutics"买入"评级,目标价从7美元升至10美元
05-13 11:46
Wedbush analyst Steven Wahrhaftig maintains CI&T (NYSE:CINT) with a Outperform and lowers the price target from $9 to $7.
05-12 21:20
CI&T (NYSE:CINT) raises FY2026 sales outlook from $548.000 million-$568.000 million to $555.800 million-$575.300 million vs $561.409 million estimate.
05-12 04:17
CI&T (NYSE:CINT) Q2 Revenue expected to be more than $140.000M vs $138.317M Est
05-12 04:17
CI&T (NYSE:CINT) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is a 14.29 percent increase over earnings of $0.07 per share from the same
05-12 04:17
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Shares of companies in the broader tech sector are trading lower amid possible ...
04-24 03:45
今日重点评级关注:Ascendiant Capital:维持RenovoRx"买入"评级,目标价从13美元升至13.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从8.25美元升至9美元
04-10 18:27
Wedbush analyst Steven Wahrhaftig assumes CI&T (NYSE:CINT) with a Outperform rating and announces Price Target of $9.
04-09 20:47
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59